Lilly's Emgality gets Priority Review for cluster headache

Lilly said FDA accepted and granted Priority Review to an sBLA for Emgality galcanezumab-gnlm to prevent episodic cluster headache in adults. A company spokesperson said the PDUFA date is in 2Q19.

The humanized mAb targeting calcitonin gene-related peptide (CGRP) has breakthrough therapy designation from FDA for the indication...